ImmunoMet Therapeutics
TX - HoustonBiotechnology
Focus: ImmunoMet Therapeutics is an oncology-focused biotech company developing small molecule therapeutics for advanced solid tumors. The company is in early-stage development with a single Phase 1 program and remains pre-revenue.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
SERIES C +
Total Funding
$39M
Open Jobs
0
About ImmunoMet Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow ImmunoMet Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
IM156
Advanced Solid TumorClinical Trials (1)
NCT03272256Phase 1 Study of IM156 in Patients With Advanced Solid Tumor and Lymphoma
Phase 1Help build intelligence for ImmunoMet Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.